Author

Míriam Mañosa

MORBID OBESITY, A NEW SUSCEPTIBILITY FACTOR FOR DEVELOPING INFLAMMATORY BOWEL DISEASE. RESULTS OF A POPULATION-BASED STUDY
MORBID OBESITY, A NEW SUSCEPTIBILITY FACTOR FOR DEVELOPING INFLAMMATORY BOWEL DISEASE. RESULTS OF A POPULATION-BASED STUDY

Míriam Mañosa  et al.

CAN HOSPITAL ADMISSIONS FOR LOWER GASTROINTESTINAL BLEEDING BE REDUCED? IMPLEMENTATION OF TWO SCALES FOR THE PREDICTION OF SAFETY DISCHARGE IN A RETROSPECTIVE COHORT
CAN HOSPITAL ADMISSIONS FOR LOWER GASTROINTESTINAL BLEEDING BE REDUCED? IMPLEMENTATION OF TWO SCALES FOR THE PREDICTION OF SAFETY DISCHARGE IN A RETROSPECTIVE COHORT

Míriam Mañosa  et al.

PATHOLOGIC INVOLVEMENT OF THE FARNESOID X RECEPTOR/FIBROBLAST GROWTH FACTOR 19 AXIS TO THE CROHN’S DISEASE EARLY POSTSURGICAL RECURRENCE
PATHOLOGIC INVOLVEMENT OF THE FARNESOID X RECEPTOR/FIBROBLAST GROWTH FACTOR 19 AXIS TO THE CROHN’S DISEASE EARLY POSTSURGICAL RECURRENCE

Míriam Mañosa  et al.

LONG-TERM TRENDS IN TARGETED THERAPIES USAGE IN INFLAMMATORY BOWEL DISEASE: TRENDY STUDY OF ENEIDA
LONG-TERM TRENDS IN TARGETED THERAPIES USAGE IN INFLAMMATORY BOWEL DISEASE: TRENDY STUDY OF ENEIDA

Míriam Mañosa  et al.

BENEFITS OF PAEDIATRIC TO ADULT TRANSITION PROGRAM IN INFLAMMATORY BOWEL DISEASE: THE BUTTERFLY STUDY OF GETECCU
BENEFITS OF PAEDIATRIC TO ADULT TRANSITION PROGRAM IN INFLAMMATORY BOWEL DISEASE: THE BUTTERFLY STUDY OF GETECCU

Míriam Mañosa  et al.

LONG-TERM EVOLUTION AFTER ANTI-TNF DRUG DISCONTINUATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
LONG-TERM EVOLUTION AFTER ANTI-TNF DRUG DISCONTINUATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Míriam Mañosa  et al.

PERFORMANCE OF SCREENING STRATEGIES FOR LATENT TUBERCULOSIS INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM THE ENEIDA REGISTRY OF GETECCU
PERFORMANCE OF SCREENING STRATEGIES FOR LATENT TUBERCULOSIS INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM THE ENEIDA REGISTRY OF GETECCU

Míriam Mañosa  et al.

Item 1 - 7 / 7
1